These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 7625533)

  • 1. Activity of pentostam (sodium stibogluconate) against cutaneous leishmaniasis in mice treated with neutralizing anti-interferon-gamma antibody.
    Nabors GS; Farrell JP
    Am J Trop Med Hyg; 1995 Jul; 53(1):55-60. PubMed ID: 7625533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis.
    Scharton-Kersten T; Afonso LC; Wysocka M; Trinchieri G; Scott P
    J Immunol; 1995 May; 154(10):5320-30. PubMed ID: 7730635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major.
    Belosevic M; Finbloom DS; Van Der Meide PH; Slayter MV; Nacy CA
    J Immunol; 1989 Jul; 143(1):266-74. PubMed ID: 2499629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reconstitution of C.B-17 scid mice with BALB/c T cells initiates a T helper type-1 response and renders them capable of healing Leishmania major infection.
    Varkila K; Chatelain R; Leal LM; Coffman RL
    Eur J Immunol; 1993 Jan; 23(1):262-8. PubMed ID: 8419179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-gamma response and increased production of T helper 2 cytokines.
    Krishnan L; Guilbert LJ; Russell AS; Wegmann TG; Mosmann TR; Belosevic M
    J Immunol; 1996 Jan; 156(2):644-52. PubMed ID: 8543816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice.
    Heinzel FP; Rerko RM; Ahmed F; Pearlman E
    J Immunol; 1995 Jul; 155(2):730-9. PubMed ID: 7608551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leishmania major-infected C3H mice treated with anti-IL-12 mAb develop but do not maintain a Th2 response.
    Hondowicz BD; Scharton-Kersten TM; Jones DE; Scott P
    J Immunol; 1997 Nov; 159(10):5024-31. PubMed ID: 9366430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate.
    Mullen AB; Lawrence CE; McFarlane E; Wei XQ; Carter KC
    Immunology; 2006 Nov; 119(3):348-54. PubMed ID: 16879623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T helper 1 response against Leishmania major in pregnant C57BL/6 mice increases implantation failure and fetal resorptions. Correlation with increased IFN-gamma and TNF and reduced IL-10 production by placental cells.
    Krishnan L; Guilbert LJ; Wegmann TG; Belosevic M; Mosmann TR
    J Immunol; 1996 Jan; 156(2):653-62. PubMed ID: 8543817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of interleukin-4 in BALB/c mice with established Leishmania major infections increases the efficacy of antimony therapy and promotes Th1-like responses.
    Nabors GS; Farrell JP
    Infect Immun; 1994 Dec; 62(12):5498-504. PubMed ID: 7960131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
    Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y
    J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of a Th2 population from a polarized Leishmania-specific Th1 population by in vitro culture with IL-4.
    Mocci S; Coffman RL
    J Immunol; 1995 Apr; 154(8):3779-87. PubMed ID: 7706719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
    Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
    J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFN-gamma produced in vivo during the first two days is critical for resolution of murine Leishmania major infections.
    Leiby DA; Schreiber RD; Nacy CA
    Microb Pathog; 1993 Jun; 14(6):495-500. PubMed ID: 8412622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection.
    Bimal S; Sinha S; Singh SK; Narayan S; Kumar V; Verma N; Ranjan A; Sinha PK; Das VN; Pandey K; Kar SK; Das P
    Exp Parasitol; 2012 Jul; 131(3):274-82. PubMed ID: 22580024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
    Li J; Nolan TJ; Farrell JP
    Exp Parasitol; 1997 Sep; 87(1):47-57. PubMed ID: 9287957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
    Bretscher PA; Ogunremi O; Menon JN
    Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [TH1 response in the experimental infection with Trypanosoma cruzi].
    Cardoni RL; Antúnez MI; Abrami AA
    Medicina (B Aires); 1999; 59 Suppl 2():84-90. PubMed ID: 10668248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis.
    Narayan S; Bimal S; Singh SK; Gupta AK; Singh VP; Sinha PK; Das P
    Exp Parasitol; 2009 Jan; 121(1):69-75. PubMed ID: 18948098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.